Source: GEN - Genetic Engineering and Biotechnology News, by Gail Dutton. AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- BeOne Medicines increased CHO-cell antibody productivity by 30% for monoclonals, 32% for trispecifics, and 50% for bispecifics using Pabpc1 overexpression.
- Pabpc1-overexpressing CHO cells grew similarly to controls, retained virtually identical product quality attributes, and accumulated less lactate and ammonia.
- The mechanism remains incompletely understood, and the strategy has not been studied in HEK293 or PER.C6 production cells.
Researchers at BeOne Medicines report that increasing expression of a gene called Pabpc1 raised antibody production in Chinese hamster ovary, or CHO, cells by roughly 30% to 50%. CHO cells are the workhorses of modern biologic drug manufacturing, used to make many therapeutic antibodies because they can grow at industrial scale and add molecular features needed for medicines to function properly. The gains appeared across monoclonal, bispecific, and trispecific antibodies, with the largest increase seen for bispecific antibodies. Importantly, the engineered cells grew at essentially the same rate as control cells carrying an empty vector, a DNA construct without the test gene. They also produced antibodies with quality attributes that were virtually indistinguishable from controls. The intervention reduced accumulation of lactate and ammonia, two metabolic by-products that can make cell-culture conditions less favorable. The results point to Pabpc1 as a potentially useful screening target for improving yields in selected CHO production cell lines. The work does not yet explain every molecular step behind the effect, but it offers a focused genetic strategy for a stubborn manufacturing problem: producing more complex protein medicines without simply building bigger bioreactors.
A Gene That Helps Cells Read Messages
Pabpc1 encodes cytoplasmic poly(A)-binding protein 1, a protein involved in managing messenger RNA, or mRNA. mRNA is the temporary genetic instruction sheet that cells use to assemble proteins. A useful analogy is a recipe card in a busy kitchen: if the card stays readable longer and reaches the cook efficiently, more dishes can be made from the same instructions.
The poly(A) portion of an mRNA molecule is a string of chemical building blocks at one end of the message. Pabpc1 binds this tail and helps influence mRNA stability and translation, the process by which cellular machinery reads an mRNA sequence to make a protein. The BeOne team noted that Pabpc1 can extend the lifetime of target mRNAs and has roles connected to mRNA stability and pre-mRNA splicing, an earlier step in preparing genetic messages.
Testing the Effect in Production Clones
The researchers overexpressed Pabpc1 in several low-expression CHO clones making three antibody formats: monoclonal antibodies, bispecific antibodies, and trispecific antibodies. Monoclonal antibodies bind one target, while bispecific and trispecific antibodies are engineered to recognize two or three targets, respectively. Those more elaborate molecules can be especially demanding for cells to assemble and secrete correctly.
Compared with controls, Pabpc1-overexpressing cells showed a 50% productivity increase for bispecific antibodies, a 32% increase for trispecific antibodies, and a 30% increase for monoclonal antibodies. The pattern suggests that the genetic change may be particularly useful where the protein product is structurally complex or where a host cell has a translation-related production bottleneck. Yet the effect was not presented as a universal solution for every engineered gene or every CHO cell line.
More Output Without an Obvious Growth Penalty
In cell manufacturing, higher output is valuable only if it does not create a new problem elsewhere. Cells that divide poorly, die early, or make a less consistent product can erase the benefit of an initial titer increase. In these experiments, growth rates were essentially the same in Pabpc1-overexpressing cells and in empty-vector controls.
The team also found that measured quality attributes were virtually identical between the two groups. That observation matters because antibody makers monitor characteristics such as structural consistency and other product features throughout development. A productivity intervention that changes those attributes could require additional process work, while a change that preserves them may be easier to evaluate in a manufacturing setting.
Metabolism May Be Part of the Advantage
The cells with elevated Pabpc1 accumulated less lactic acid and ammonia than control cells. These molecules are normal products of cellular metabolism, but they can become troublesome when they build up in a culture. Like exhaust collecting in an enclosed workshop, excessive by-products can create conditions that make productive work harder for the cells.
BeOne's researchers proposed that Pabpc1 may regulate cellular metabolism to some degree by reducing these potentially toxic accumulations. That would create a more favorable environment for protein production. The observation links improved antibody titers not only to how efficiently cells read genetic instructions, but also to the health of the cellular production environment over the course of culture.
A Clue at the Start of Translation
The team reported an interaction between Pabpc1 and eukaryotic initiation factor 4E, or eIF4E. Translation initiation is the stage at which a cell's protein-making machinery is recruited to an mRNA message. It is similar to opening a book to the correct page before reading can begin: even a well-preserved instruction sheet cannot produce much if the reading process starts inefficiently.
The reported Pabpc1 and eIF4E interaction may trigger downstream reactions that improve translation initiation efficiency. That provides a plausible connection between extra Pabpc1 and higher recombinant protein output. Recombinant proteins are proteins made by cells that have been given introduced genetic instructions, a core approach used for many antibody medicines.
Not Every Genetic Lever Works
The contrast with five other tested genes underscores how selective cell-line engineering can be. The researchers also overexpressed Slc25a32, Il19, Ptdss1, Stk3, and Mtdh, but none produced results comparable to Pabpc1. Adding a gene is therefore not like installing a universal performance upgrade; its value depends on whether its biological function addresses the particular constraint limiting that host cell.
The team emphasized that gains in productivity per cell and in overall culture titer depend on the fit between a gene's function and the intrinsic productivity bottlenecks in the host. This is a practical point for manufacturers. Instead of expecting one modification to lift all programs, developers may need to screen interventions against particular cell lines and particular protein products.
Why This Matters
Biologic medicines are often difficult and expensive to manufacture because living cells must produce them reliably at large scale. Even a moderate increase in titer, the amount of protein produced in a culture, can affect how much material a facility can make from a given run. Improvements that retain cell growth and product quality are especially attractive because they may increase output without requiring a complete redesign of the production process.
The findings may be relevant to the growing push toward more complex multispecific antibodies, which are designed to engage multiple biological targets. BeOne observed its largest reported productivity increase in bispecific antibody-producing cells. That does not establish that Pabpc1 will improve every multispecific program, but it identifies a molecular handle worth testing where expression is low.
What Comes Next
BeOne Medicines plans to refine the approach and broaden its use in biopharmaceutical manufacturing. Key next steps include clarifying exactly how Pabpc1 changes recombinant protein production and determining which CHO cell backgrounds and product types benefit most. Its applicability to other common production hosts, including human embryonic kidney 293 cells and PER.C6 cells, has not been studied, leaving an important question about how widely the strategy can travel beyond CHO cells.